Skip to main content
Search
Help
Semaglutide — 5mg vial; product photograph

Product photo · 5mg

Reports describe submitted samples for this amount and form.

Weight LossAppetite ControlMetabolic Health

Semaglutide

A drug studied for blood sugar, weight management and heart-related outcomes.

Questions? Book a Free CallPeptify Analytics report (opens in a new tab)Mixing helper
Select strength
What does the amount mean?

10 mg is an amount of material. Read the label to see whether it means per vial, per tablet, or per package.

Read more
$50.00 CADsubtotal

1 vial · 5mg in each vial

Quantity
1

You can add this product to your cart. Checkout is temporarily unavailable.

Lab results
The research guide

Semaglutide, explained

A drug studied for blood sugar, weight management and heart-related outcomes.

Published randomized clinical trialsRead the sources

What it’s used for

Human studies

Weight loss

A 2.4 mg weekly trial reported 14.9% loss at 68 weeks versus 2.4% with placebo. A 7.2 mg study reported 18.7% at 72 weeks.

Approved medicine context

Blood-sugar control

Specific approved semaglutide medicines improve blood-sugar control in diabetes.

Approved medicine context

Heart risk

Wegovy is approved to reduce certain serious heart and blood-vessel risks.

Approved medicine context

Fatty liver

Wegovy injection has accelerated approval for adults with an inflammatory fatty-liver condition, MASH, and F2–F3 liver scarring, without cirrhosis.

Community reports

Appetite

People report reduced appetite and cravings, with easier weight maintenance.

What to expect

  1. Weeks 1–4

    Blood-sugar changes

  2. Months 2–6+

    Weight loss builds up gradually

  3. Week 68

    14.9% average loss on 2.4 mg in a large trial

Side effects & safety

Side effects

  • Nausea, vomiting, diarrhea and constipation
  • Fatigue, headache and hair loss
  • Altered skin sensations, more common at the 7.2 mg dose along with stomach effects
  • Slower stomach emptying, which can affect how oral medicines are absorbed
  • Label warnings include pancreatitis, gallbladder disease and dehydration-related kidney injury
  • Retinopathy (eye damage) and aspiration are also listed risks

Stop and get help if

  • Abdominal pain
  • Yellowing of the skin or eyes (jaundice)
  • Swelling in the neck
  • Trouble breathing or signs of an allergic reaction
  • Passing very little urine
  • Vision changes
  • Confusion or fainting

Avoid or check first

  • Personal or family history of medullary thyroid cancer (MTC) or MEN2 — contraindicated under a boxed warning
  • Pregnant or planning pregnancy — the label says to stop at least 2 months before a planned pregnancy
  • Taking insulin or sulfonylureas — higher risk of low blood sugar
  • Using another semaglutide or GLP-1 product — taking them together isn't recommended

In sport

  • The reference describes semaglutide as not prohibited, while noting WADA monitoring of GLP-1 medicines.

How much people usually take

Weight loss initiation

Weekly × 4 weeks, then increase · injectable

0.25 mg

Weight loss maintenance

Weekly (after 16-week titration) · injectable

2.4 mg

Diabetes management

Weekly · injectable

0.5–1 mg

Weight reduction: STEP 1

Once weekly · 68 weeks · injectable

2.4 mgtarget

Weight reduction: Wegovy

Once weekly; step up every 4 weeks · 2.4 mg maintenance from week 17 · injectable

0.25 mg → 0.5 mg→ 1 mg → 1.7 mg → 2.4 mg

Diabetes initiation (Rybelsus)

Daily × 30 days · oral

3 mg

Standard diabetes dose (Rybelsus)

Once daily · oral

7 mg

Maximum diabetes dose (Rybelsus)

Once daily · oral

14 mg

Weight loss initiation (oral Wegovy)

Daily × 4 weeks · oral

1.5 mg

Weight loss escalation 1 (oral Wegovy)

Daily × 4 weeks · oral

4 mg

Weight loss escalation 2 (oral Wegovy)

Daily × 4 weeks · oral

9 mg

Weight loss maintenance (oral Wegovy)

Once daily · oral

25 mg

How to mix and store it

How many units do I draw?

mL
Draw to10units0.1 mL
U-100 syringe volume reference, 30 units = 0.3 mL051015202530
Resulting concentration2.5 mg/mL
How to mix5 steps

  1. Wipe both tops

    Wash your hands, then swab both rubber vial tops with alcohol. Let them dry.

  2. Draw the water

    Use a new sterile syringe to draw the water volume selected in the calculator.

  3. Run it down the wall

    Introduce the water slowly down the inside glass wall, rather than directly onto the powder.

  4. Swirl, don’t shake

    Gently swirl or roll the vial. Allow time for the powder to dissolve.

  5. Label the vial

    Write the preparation date and the amount and final volume on the vial label.

Injecting under the skinWhere, rotating sites, which syringe

Where

Subcutaneous injections go into the fatty layer beneath the skin. Common sites include the abdomen, outer thigh and upper arm. Keep at least 5 cm from the navel and avoid bruised, irritated or damaged skin.

Rotate sites

Change the spot each time. Clean the skin and let it dry.

Single-use equipment

Use a new sterile needle and syringe each time. Place used needles in a sharps container.

Storage

Storage

Refrigerated at 2–8°C.

Combining it with others

Don’t combine

  • Tirzepatide

    They affect the same appetite hormone, GLP-1.

  • Retatrutide

    They affect the same appetite hormone, GLP-1.

  • Survodutide

    They affect the same appetite hormone, GLP-1.

  • Mazdutide

    They affect the same appetite hormone, GLP-1.

  • Orforglipron

    They affect the same appetite hormone, GLP-1.

Often taken together

  • Cagrilintide

    The studied combination uses a different prepared product.

What the research says

GLP-1 signaling

Semaglutide acts on the appetite hormone GLP-1. Tirzepatide acts on both GIP and GLP-1 hormone signals.

What studies found

STEP 1

Human study · 1,961 adults · 68 weeks

In 1,961 adults without diabetes, average weight change at 68 weeks was −14.9% with semaglutide versus −2.4% with placebo. Both groups received lifestyle support. The main analysis included people who stopped treatment or needed additional treatment.

SELECT

Human study · heart disease, no diabetes

SELECT followed 17,604 adults with heart or blood-vessel disease and no diabetes for an average 39.8 months. Death from those diseases, a nonfatal heart attack or a nonfatal stroke occurred in 6.5% versus 8.0% with placebo (risk estimate 0.80). Reported health problems caused permanent treatment stops in 16.6% versus 8.2%.

How long it stays in your body

Half-life is the time it takes for the amount in the body to fall by half. It does not tell you how long effects last.

Half-life≈ 7 days
Mostly cleared35 daysAbout 97% gone after five half-lives
Half-lifeUnder-the-skin injection in the study
50%Estimated amount left
7 daysAfter one dose
Illustrative Semaglutide half-life model: 50% remaining after 7 days. Normalized single exponential decline, not measured individual blood levels.0%50%100%0 d7 d14 d21 d28 d35 d

Drag to see how much is left over time.

What it’s made of

Length31-residue backbone
Molecular weight4113.58 g/mol
FormulaC187H291N45O59

Sequence 31 · N → C

  1. His
  2. Aib
  3. Glu
  4. Gly
  5. Thr
  6. Phe
  7. Thr
  8. Ser
  9. Asp
  10. Val
  11. Ser
  12. Ser
  13. Tyr
  14. Leu
  15. Glu
  16. Gly
  17. Gln
  18. Ala
  19. Ala
  20. Lys
  21. Glu
  22. Phe
  23. Ile
  24. Ala
  25. Trp
  26. Leu
  27. Val
  28. Arg
  29. Gly
  30. Arg
  31. Gly

N-to-C backbone. Aib is alpha-aminoisobutyric acid. The label’s native GLP-1 numbering calls the acylated residue Lys26; it is token 20 of this shorter backbone. The C18 fatty-diacid spacer is separate from the tokens.

Molecular notes

Semaglutide as described in the Ozempic injection label. Molecular reference information does not verify the selected Monroe material.

Lab results

5mg · 1 linked report

Purity · sample result
99.342% / 99.334% / 99.481%
Amount found · Semaglutide
Sample 1: 5.23 mgSample 2: 4.82 mgSample 3: 5.05 mg

Separate sample results, in report order.

These are submitted-sample results, separate from general research or popularity ratings. Report presentation: Peptify Analytics. Source laboratory: Janoshik Analytical. The connection to the batch you would receive is not confirmed here.

Videos worth watching

Research conversations, with their original context.

NEJM Group · 2023-12-14Semaglutide and Cardiovascular Outcomes in Obesity | NEJMThe publisher's short explanation of SELECT's clinical research question. Publisher metadata checked; video not watched. (opens in a new tab)Dr. Dustin PortelaWhat You Need To Know Before Taking Ozempic - Doctor Answers (opens in a new tab)Dr. Spencer NadolskyTop 5 GLP-1 Side Effects and How to Fix Them | Doctor Explains (opens in a new tab)Dr. Jones, DCDoctor Explains The REAL Side Effects of Ozempic & Mounjaro (not what you think) (opens in a new tab)Dr. Dustin PortelaOzempic is Making Your Hair Fall Out - Here's What Doctors Won't Tell You (opens in a new tab)Dr. Alex TatemRetatrutide vs Semaglutide vs Tirzepatide: Who Wins the Fat-Loss War? #fatloss #shortsvideo (opens in a new tab)

Product details

Form
Vial
Amount
5mg

Sources & further reading

Follow each reference to its original publication or documentation.

Questions

What does 5mg mean?

It describes an amount of material in the unit stated on the label. It does not describe liquid volume, a dose, or how to prepare the product.

Read more about amounts
Does purity mean it is sterile?

No. Purity and sterility require different tests. An endotoxin result also does not establish sterility.

About testing
Can I calculate concentration?

You need a mass in mg and either a final volume or a target concentration. IU and blends require separate, verified information.

Use the mixing helper for this amount ↑
How can I get help with an order?

Open your order details to check its current status. Shipping and support information are available below.

Contact us

More to explore

Shop all